Evidence map›Paper›PMID 41409641›Full record

ArticleNeuromethods2024

Gene editing and reprogramming of human fibroblast cells (hFBs) to human pluripotent stem cells (hiPSCs).

Zhe Zhang, Shinghua Ding

Abstract read
In one paragraph

Article in Neuromethods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhe ZhangDepartment of Chemical and Biomedical Engineering (ChBME), University of Missouri, Columbia, MO, USA.
Shinghua DingDepartment of Chemical and Biomedical Engineering (ChBME), University of Missouri, Columbia, MO, USA.

Funding

The Role of Gliotransmission in Cerebral IschemiaR01NS069726 · NINDS · UNIVERSITY OF MISSOURI-COLUMBIA · PI DING, SHINGHUA · 2010 to 2022
$3.3M
Pathogenesis and motor neuron degeneration of a novel disease associated with a P158A mutation in NAMPTR01NS123023 · NINDS · UNIVERSITY OF MISSOURI-COLUMBIA · PI Shinghua Ding · 2022 to 2026
$2.3M
NINDS NIH HHS R01 NS069726NINDS NIH HHS R01 NS123023
6 · The paper itself

Abstract

Predictive disease models play significant roles in advancing our knowledge of the pathology of human disease. In this field, animal models have been extensively employed and have provided crucial insights into the pathophysiological mechanisms of human disease. However, they often fail to fully capture many human phenotypes due to significant species differences in genomic responses. Human induced pluripotent stem cells (hiPSCs) are genetically reprogrammed cells that exhibit qualities remarkably similar to those of embryonic stem cells (ESC) and have emerged as a promising source for cell therapy and fundamental research in pathology. The ability to reprogram human fibroblast cells (hFBs) to iPSCs provides an opportunity to model human diseases. However, even hiPSCs from different persons have different genetic background, thus generation of isogenic unaffected control hiPSCs is necessary to study model human disease. Here, we describe methods to generate isogenic hFBs using CRISPR/Cas9 gene editing method, and subsequently reprogram them into iPSCs using commercially available Sendai virus vectors. Specifically, using the CRISPR/Cas9 system and Sendai virus vector, isogenic iPSC lines can be generated. This protocol provides a structured approach for obtaining multiple isogeneic hiPSC lines, which facilitate the modeling of various human diseases.

Indexed as

CRISPR/Cas 9 gene editinghuman fibroblastisogenic iPSCsReprogrammingSendai vectors

Identifiers

PMID41409641
PMCPMC12707990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.